Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1988 1
1989 2
1991 1
1992 1
1993 3
1995 2
1997 1
1998 1
2001 1
2007 2
2008 3
2009 5
2010 7
2011 9
2012 7
2013 13
2014 18
2015 16
2016 23
2017 22
2018 24
2019 39
2020 30
2021 42
2022 33
2023 53
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Results by year

Filters applied: . Clear all
Page 1
Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses.
Tremain AC, Wallace RP, Lorentz KM, Thornley TB, Antane JT, Raczy MR, Reda JW, Alpar AT, Slezak AJ, Watkins EA, Maulloo CD, Budina E, Solanki A, Nguyen M, Bischoff DJ, Harrington JL, Mishra R, Conley GP, Marlin R, Dereuddre-Bosquet N, Gallouët AS, LeGrand R, Wilson DS, Kontos S, Hubbell JA. Tremain AC, et al. Among authors: solanki a. Nat Biomed Eng. 2023 Sep;7(9):1142-1155. doi: 10.1038/s41551-023-01086-2. Epub 2023 Sep 7. Nat Biomed Eng. 2023. PMID: 37679570
NRG brain tumor specialists consensus guidelines for glioblastoma contouring.
Kruser TJ, Bosch WR, Badiyan SN, Bovi JA, Ghia AJ, Kim MM, Solanki AA, Sachdev S, Tsien C, Wang TJC, Mehta MP, McMullen KP. Kruser TJ, et al. Among authors: solanki aa. J Neurooncol. 2019 May;143(1):157-166. doi: 10.1007/s11060-019-03152-9. Epub 2019 Mar 19. J Neurooncol. 2019. PMID: 30888558 Free PMC article.
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Schürer S, Swarbrick A, Sykes DB, Patnaik A. Chaudagar K, et al. Among authors: solanki a. Clin Cancer Res. 2023 May 15;29(10):1952-1968. doi: 10.1158/1078-0432.CCR-22-3350. Clin Cancer Res. 2023. PMID: 36862086 Free PMC article.
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker.
Mansurov A, Hosseinchi P, Chang K, Lauterbach AL, Gray LT, Alpar AT, Budina E, Slezak AJ, Kang S, Cao S, Solanki A, Gomes S, Williford JM, Swartz MA, Mendoza JL, Ishihara J, Hubbell JA. Mansurov A, et al. Among authors: solanki a. Nat Biomed Eng. 2022 Jul;6(7):819-829. doi: 10.1038/s41551-022-00888-0. Epub 2022 May 9. Nat Biomed Eng. 2022. PMID: 35534574
Editorial Commentary.
Koehne EL, Solanki AA, Gorbonos A. Koehne EL, et al. Among authors: solanki aa. Urol Pract. 2022 Sep;9(5):412-413. doi: 10.1097/UPJ.0000000000000316.01. Epub 2022 Jun 22. Urol Pract. 2022. PMID: 37145761 No abstract available.
EDITORIAL COMMENT.
Solanki AA, Efstathiou JA. Solanki AA, et al. Urology. 2019 Nov;133:171-172. doi: 10.1016/j.urology.2019.05.063. Urology. 2019. PMID: 31706416 No abstract available.
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A, Carnevalli LS, Sinclair C, Johnson B, Peter A, Taylor M, Hettrick L, Chapman M, Klein S, Solanki A, Gattis D, Watt A, Hughes AM, Magiera L, Kar G, Ireland L, Mele DA, Sah V, Singh M, Walton J, Mairesse M, King M, Edbrooke M, Lyne P, Barry ST, Fawell S, Goldberg FW, MacLeod AR. Revenko A, et al. Among authors: solanki a. J Immunother Cancer. 2022 Apr;10(4):e003892. doi: 10.1136/jitc-2021-003892. J Immunother Cancer. 2022. PMID: 35387780 Free PMC article. Clinical Trial.
Cranial Base Meningiomas.
Prabhu VC, Melian E, Germanwala AV, Solanki AA, Borys E, Barton K, Anderson DE. Prabhu VC, et al. Among authors: solanki aa. World Neurosurg. 2018 Jan;109:258-262. doi: 10.1016/j.wneu.2017.09.207. Epub 2017 Oct 7. World Neurosurg. 2018. PMID: 29017978 No abstract available.
Evolving targets for the treatment of atherosclerosis.
Solanki A, Bhatt LK, Johnston TP. Solanki A, et al. Pharmacol Ther. 2018 Jul;187:1-12. doi: 10.1016/j.pharmthera.2018.02.002. Epub 2018 Feb 4. Pharmacol Ther. 2018. PMID: 29414673 Review.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: solanki a. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
336 results